# Golimumab

## Simponi inj 50mg/0.5mL

##### 臨採

| 藥品代碼   | ISIM                                                                                                                                                                                                                                                                                                                                                    |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | In combination w/ methotrexate for the treatment of moderate to severe active RA. Alone or in combination w/ methotrexate for active psoriatic arthritis (PsA). Treatment of active ankylosing spondylitis (AS).                                                                                                                                        |
| 用法用量   | SC， rheumatoid arthritis， psoriatic arthritis and ankylosing spondylitis 50 mg once a month. Moderate to severe active ulcerative colitis( body weight<80 kg) 200 mg at week 0， then 100 mg at week 2， followed by 50-100 mg every 4 weeks.( body weight > or = 80kg) 200 mg at week 0， then 100 mg at week 2， followed by 100 mg every 4 weeks.  |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                            |
| 禁忌       | Canadian labeling: Hypersensitivity to golimumab， latex， or any other component of formulation or packaging; patients with severe infections (eg， sepsis， tuberculosis， opportunistic infections); moderate or severe heart failure (NYHA class III/IV)                                                                                            |
| 副作用     | Serious infections， malignancies， autoimmune disorders & autoantibodies， inj site reactions， new onset & exacerbations of psoriasis， immunogenicity， upper resp tract infection， nasopharyngitis， sepsis， increased ALT & AST; HTN， bronchitis， dizziness， sinusitis， flu， pharyngitis， rhinitis， pyrexia， oral herpes， paraesthesia. |
| 孕期建議   | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                  |
| 哺乳期建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                     |

